SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (20024)5/4/1998 3:17:00 PM
From: Sleepman  Read Replies (1) | Respond to of 32384
 
I agree. I think that the Entremed news is certainly encouraging, but even if the FDA rushes through this, it will be years before the drug is available. Also, it will be necessary to use other drugs in combination to help the ENMD drug out.
The stock that is now in the 50's will soon be back in the 20's or even teens as people tire of the hype and want results.
LGND does indeed have compounds that have antiangiogenic properties. It also has a much broader set of disease indications for which it is pursuing drugs. It will take some time, but this company will be a powerhouse. I think that all the naysayers will eventually eat their words.
If you want instant money, go elsewhere, but if you want a very good medium to long term bet, stay with Ligand. Dan



To: Torben Noerup Nielsen who wrote (20024)5/4/1998 3:23:00 PM
From: tonyt  Respond to of 32384
 
>I'm pretty sure LGND's experiments were done on rats; not mice :-). I'd rate the
>rat model as slightly more realistic.

Maybe so, but the tone of the WSJ story was a little bit better than LGND's pr:

"Entremed's shares soared on Monday in the wake of a weekend report that a combination of drugs it plans to make has been proven to kill cancer in mice."


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News